Clik here to view.
Alteogen Announces Completion of Phase 1 Clinical Trial of Aflibercept...
DAEJEON, South Korea Alteogen Inc. (KOSDAQ:196170) announced that it has completed Phase 1 clinical trial of Eylea® Biosimilar (ALT-L9). The clinical trial was conducted at 4 major hospitals in...
View ArticleClik here to view.
UPLIZNA® (inebilizumab-cdon) Approved by Japanese Ministry of Health, Labour...
DUBLIN Horizon Therapeutics plc (Nasdaq: HZNP) today announced that its strategic partner Mitsubishi Tanabe Pharma Corporation (MTPC) has received manufacturing and marketing approval of UPLIZNA for...
View ArticleClik here to view.
美国眼镜行业零售商Costco正式采购三井化学高折射率镜片单体MRTM
东京 (美国商业资讯)–美国眼镜行业零售商Costco（英文：Costco Wholesale Corporation，总部位于美国华盛顿州，CEO：W. Craig Jelinek）正式决定采购源于三井化学株式会社（总部位于东京都港区，董事长兼总经理：桥本修）所研发的高折射率镜片原材料MRTM所生产的镜片。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
Mitsui Chemicals’ MR™ High Refractive Index Ophthalmic Lens Monomers Picked...
TOKYO Mitsui Chemicals, Inc. (Tokyo: 4183; President & CEO: HASHIMOTO Osamu) today announced that its MR™ series of high refractive index lens monomers has been picked up and launched as the...
View ArticleClik here to view.
CHMP Recommends EU Approval of Chugai’s Enspryng (Satralizumab) for...
TOKYO Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that Roche has received notification that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use...
View ArticleClik here to view.
KKR Invests US$95 million in Lenskart
NEW DELHI & MUMBAI, India Lenskart, a leading omni-channel eyewear retailer in India, and KKR, a global investment firm, today announced the signing of definitive agreements under which KKR will...
View ArticleClik here to view.
Benefits in a Pandemic: NaturalVue® Offers Multiple Solutions for Patients...
ATLANTA US-based medical device company and producer of the NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lenses (‘NaturalVue MF’) Visioneering Technologies, Inc (ASX: VTI) (‘Visioneering’,...
View ArticleClik here to view.
Arnaud Lacoste Is Named Chief Scientific Officer of Aurion Biotech
SEATTLE & BOSTON & TOKYO Arnaud Lacoste, MBA, PhD, has been named chief scientific officer of Aurion Biotech, whose mission is to cure blindness by developing a differentiated platform of...
View ArticleClik here to view.
PanOptica Announces Licensing Agreement with Zhaoke Ophthalmology for...
MOUNT ARLINGTON, N.J. PanOptica, Inc. today confirms the licensing agreement with Zhaoke Ophthalmology Limited (HKEX Stock Code: 6622.HK) to develop and commercialize PAN-90806, an investigational...
View ArticleClik here to view.
Ciba Vision Johor Sdn. Bhd. also known as ALCON Johor earns the best place to...
KUALA LUMPUR, Malaysia Alcon Johor, an affiliate of the largest eye care device company in the world with 75 years heritage, present in over 70 countries and serving patients in more than 140...
View ArticleClik here to view.
Santen Receives FDA Approval for Verkazia™ (Cyclosporine Ophthalmic Emulsion)...
EMERYVILLE, Calif. Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co., Ltd. (hereinafter, Santen), a global company focused exclusively on eye care, today announced that the U.S. Food and...
View ArticleClik here to view.
Chugai’s Enspryng (Satralizumab) Approved by European Commission as First...
TOKYO Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that Roche has been granted Marketing Authorization from the European Commission for the pH-dependent binding humanized anti-IL-6...
View ArticleClik here to view.
Teva and Bioeq Announce Commercial Partnership for Biosimilar
TEL AVIV, Israel & ZURICH Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) and Bioeq AG (“Bioeq”) today announced that they have entered into a strategic partnership for the exclusive...
View ArticleClik here to view.
Aurion Biotech Names Edward Holland, MD, Chief Medical Advisor
SEATTLE & BOSTON & TOKYO Edward Holland, MD, has been named chief medical advisor of Aurion Biotech, whose mission is to cure blindness by developing a differentiated platform of advanced...
View ArticleClik here to view.
MENAGEN-MiddleEast announces commercializing agreement with CKD for...
DUBAI, United Arab Emirates Menagen Pharmaceutical Industries (“Menagen”) and Chong Kun Dang Pharmaceutical Corp (“CKD”) Korea announced today that they have entered into a strategic partnership in...
View ArticleClik here to view.
Aurion Biotech Appoints Professor Shigeru Kinoshita, MD, PhD, to Its Medical...
SEATTLE & BOSTON & TOKYO Shigeru Kinoshita, MD, PhD, has joined the medical advisory board at Aurion Biotech, whose mission is to cure blindness by developing a differentiated platform of...
View ArticleClik here to view.
Topcon Healthcare Acquires VISIA Imaging
TOKYO Topcon Corporation, a leading provider of medical devices and software solutions for the global eye care community, announced today that it has acquired VISIA Imaging S.r.l, an ophthalmic...
View ArticleClik here to view.
Aurion Biotech Announces IOTA Cell Therapy Trial
SEATTLE & BOSTON & TOKYO Aurion Biotech, whose mission is to cure blindness by developing a differentiated platform of advanced therapies to treat ocular diseases, today announced...
View ArticleClik here to view.
Santen and IAPB Taking Action to Implement the First Ever UN General Assembly...
OSAKA, Japan Santen Pharmaceutical Co., Ltd. (“Santen”) announced today that Santen, in partnership with the International Agency for the Prevention of Blindness (IAPB), will take action to...
View ArticleClik here to view.
参天制药和国际防盲协会合作，以实际行动执行联合国大会首个确认眼部健康与可持续发展之间存在联系的决议
日本大阪 (美国商业资讯)–参天制药株式会社（Santen Pharmaceutical Co., Ltd.，简称“参天”）今天宣布，公司将与国际防盲协会(International Agency for the Prevention of Blindness,...
View Article